MARKET

LCTX

LCTX

Lineage Cell The
AMEX
1.080
0.000
0.00%
After Hours: 1.080 0 0.00% 19:30 08/21 EDT
OPEN
1.090
PREV CLOSE
1.080
HIGH
1.108
LOW
1.070
VOLUME
716.42K
TURNOVER
--
52 WEEK HIGH
2.090
52 WEEK LOW
1.000
MARKET CAP
273.14M
P/E (TTM)
-7.7033
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LCTX last week (0810-0814)?
Weekly Report · 5d ago
Lineage Maintained at Buy with Unchanged $3 Target as Cell Therapy Pipeline and DOSED SCI Trial Advance
TipRanks · 08/12 19:05
Weekly Report: what happened at LCTX last week (0803-0807)?
Weekly Report · 08/10 09:41
Lineage Cell Therapeutics Balances Progress and Risk
TipRanks · 08/08 00:13
Lineage Maintained at Buy as Analyst Cites Clinical Momentum and Strategic Backing; $9 Price Target Reaffirmed
TipRanks · 08/07 20:26
Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Lineage Therap (LCTX) and BioLife Solutions (BLFS)
TipRanks · 08/07 15:00
Lineage Cell Therapeutics GAAP EPS of -$0.03 in-line, revenue of $1.07M misses by $0.46M
Seeking Alpha · 08/06 20:54
Lineage Cell Therapeutics reports Q2 EPS (3c), consensus (3c)
TipRanks · 08/06 20:17
More
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).

Webull offers Lineage Cell Therapeutics Inc stock information, including AMEX: LCTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LCTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LCTX stock methods without spending real money on the virtual paper trading platform.